Results 71 to 80 of about 31,006 (261)

Cardiovascular Health in Women—Across the Lifespan

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Cardiovascular disease (CVD) remains the leading cause of mortality and morbidity among women worldwide. However, CVD continues to be perceived as a predominantly male issue. CVD in women therefore remains understudied, underrecognized and undertreated.
Jaya Chandrasekhar   +5 more
wiley   +1 more source

A keen eye for risk [PDF]

open access: yes, 2018
No abstract ...
Ford, Thomas J., Rocchiccioli, Paul
core   +1 more source

Real‐world treatment trajectories preceding GLP‐1 receptor agonist initiation in type 2 diabetes: A descriptive UK population‐based cohort study on adherence to national clinical guidelines

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims To investigate glucose‐lowering treatment trajectories preceding glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) initiation in UK primary care, while assessing alignment with contemporary UK clinical guidelines, considering calendar time, cardiovascular disease (CVD) history, and obesity status.
Franziska S. Ulrich   +3 more
wiley   +1 more source

Coronary Sinus Reducer: History, Current Applications, and Future Perspectives

open access: yesReviews in Cardiovascular Medicine
The coronary sinus reducer (CSR) is a percutaneous device designed to improve coronary blood flow and alleviate symptoms of refractory angina in patients with severe coronary artery disease (CAD) who are unsuitable for revascularization therapy.
Fabrizio Ugo   +5 more
doaj   +1 more source

Efficacy profile of ivabradine in patients with heart failure plus angina pectoris [PDF]

open access: yes, 2016
Objectives: In the Systolic Heart Failure Treatment with the If Inhibitor Ivabradine Trial (SHIFT), slowing of the heart rate with ivabradine reduced cardiovascular death or heart failure hospitalizations among patients with systolic chronic heart ...
Borer, Jeffrey S.   +9 more
core   +1 more source

Economic burden of type 2 diabetes management in France according to clinical characteristics

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aim We sought to investigate the treatment, medication patterns, and economic burden of type 2 diabetes (T2D) in France. Materials and Methods This was a descriptive retrospective cross‐sectional study of a representative sample of adults in the national healthcare system claims database in 2022.
Bruno Guerci   +9 more
wiley   +1 more source

Cost‐effectiveness analysis of Dexcom ONE+ real‐time continuous glucose monitoring versus self‐monitoring of blood glucose in people with type 2 diabetes in Aotearoa New Zealand

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Real‐time continuous glucose monitors (rt‐CGM) have been found effective and economical for the treatment of diabetes in many countries. The objective of this study was to provide a cost‐effectiveness analysis of rt‐CGM versus self‐monitoring of blood glucose (SMBG) from the perspective of a healthcare payer in New Zealand.
Ryan G. Paul   +4 more
wiley   +1 more source

Sex‐Specific Associations of Inflammatory Biomarkers With All‐Cause and Cardiovascular Mortality Across Glycaemic Status: A Prospective UK Biobank Study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To explore sex‐specific heterogeneity in the prognostic discrimination of inflammatory markers for mortality across different glycaemic states. Methods This prospective cohort study included 450 438 participants from the UK Biobank (median follow‐up: 15.3 years), stratified by sex and glycaemic status.
Yawen Zhang   +5 more
wiley   +1 more source

Acute complications of percutaneous transluminal coronary angioplasty for total occlusion [PDF]

open access: yes, 1991
The incidence of major complications after percutaneous coronary angioplasty (PTCA) of a totally occluded artery was assessed retrospectively. A total of 1649 PTCA procedures were analyzed. After exclusion of procedures for acute myocardial infarction or
Brand, M.J.B.M. (Marcel) van den   +8 more
core   +2 more sources

Home - About - Disclaimer - Privacy